Correction: novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs

[1]  Taher Abbasi,et al.  Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs , 2014, Journal of Translational Medicine.

[2]  Kelly A. Frazer,et al.  High-Resolution Mutational Profiling Suggests the Genetic Validity of Glioblastoma Patient-Derived Pre-Clinical Models , 2013, PloS one.

[3]  S. Bojesen,et al.  Statin use and reduced cancer-related mortality. , 2012, The New England journal of medicine.

[4]  M. Levis,et al.  Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. , 2012, Blood.

[5]  Oliver Nussbaumer,et al.  Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents , 2012, Clinical Cancer Research.

[6]  L. Parada,et al.  Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells , 2012, Cell.

[7]  T. Gao,et al.  Excessive Autophagy Contributes to Neuron Death in Cerebral Ischemia , 2012, CNS neuroscience & therapeutics.

[8]  Yeni Kim,et al.  The tricyclic antidepressant imipramine induces autophagic cell death in U-87MG glioma cells. , 2011, Biochemical and biophysical research communications.

[9]  B. Liu,et al.  Enhanced invasion in vitro and the distribution patterns in vivo of CD133+ glioma stem cells. , 2011, Chinese medical journal.

[10]  Takao Satou,et al.  Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma , 2011, Journal of experimental & clinical cancer research : CR.

[11]  M. Salacz,et al.  Glioblastoma: Part I. Current state of affairs. , 2011, Missouri medicine.

[12]  A. Mackay-Sim,et al.  A comparative study of the structural organization of spheres derived from the adult human subventricular zone and glioblastoma biopsies. , 2011, Experimental cell research.

[13]  W. Yung,et al.  Advances in translational research in neuro-oncology. , 2011, Archives of neurology.

[14]  T. Nakanishi,et al.  Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1. , 2011, Drug metabolism and pharmacokinetics.

[15]  M. Prados,et al.  An LXR agonist promotes GBM cell death through inhibition of an EGFR / AKT / SREBP-1 / LDLR-dependent pathway , 2011 .

[16]  R. Kast.  Glioblastoma: synergy of growth promotion between CCL5 and NK‐1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti‐HIV drug and blocking NK‐1R with aprepitant, an FDA approved anti‐nausea drug , 2010, Journal of clinical pharmacy and therapeutics.

[17]  Manas Tandon,et al.  Orphan drug: Development trends and strategies , 2010, Journal of pharmacy & bioallied sciences.

[18]  Edward H. Kerns,et al.  Insights for Predicting Blood-Brain Barrier Penetration of CNS Targeted Molecules Using QSPR Approaches , 2010, J. Chem. Inf. Model..

[19]  P. Duffner.  Risk factors for cognitive decline in children treated for brain tumors. , 2010, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[20]  T. Yawata,et al.  Enhanced MDR1 Expression and Chemoresistance of Cancer Stem Cells Derived from Glioblastoma , 2009, Cancer investigation.

[21]  Y. Ho,et al.  Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. , 2009, World journal of gastroenterology.

[22]  Mark Bernstein,et al.  Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. , 2009, Cell stem cell.

[23]  N. Hayashi,et al.  Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-kappa B activation in human glioma cell lines. , 2009, Journal of neurosurgery.

[24]  H. Friedman,et al.  Experience with irinotecan for the treatment of malignant glioma. , 2009, Neuro-oncology.

[25]  Lucienne Juillerat-Jeanneret,et al.  The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? , 2008, Drug discovery today.

[26]  R. Kiss,et al.  Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. , 2008, Neoplasia.

[27]  M. Mrugala,et al.  Mechanisms of Disease: temozolomide and glioblastoma—look to the future , 2008, Nature Clinical Practice Oncology.

[28]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[29]  Xiaofeng Yang,et al.  Identification of cancer stem-like cells in the C6 glioma cell line and the limitation of current identification methods , 2008, In Vitro Cellular & Developmental Biology - Animal.

[30]  A. Heerschap,et al.  Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization , 2008, Molecular Cancer Therapeutics.

[31]  N. Matsumoto,et al.  Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. , 2007, Biological & pharmaceutical bulletin.

[32]  Dai Fukumura,et al.  Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize , 2007, Journal of cellular biochemistry.

[33]  E. Raymond,et al.  Lessons learned in the development of targeted therapy for malignant gliomas , 2007, Molecular Cancer Therapeutics.

[34]  Mike Tyers,et al.  Chemical genetics reveals a complex functional ground state of neural stem cells. , 2007, Nature chemical biology.

[35]  James J. Wolff,et al.  Pharmacogenetics and irinotecan therapy. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[36]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[37]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[38]  J. Verweij,et al.  Role of pharmacogenetics in irinotecan therapy. , 2006, Cancer letters.

[39]  Susan A Charman,et al.  Methods to assess drug permeability across the blood‐brain barrier , 2006, The Journal of pharmacy and pharmacology.

[40]  C. Cleeland,et al.  The role of statins in cancer therapy. , 2006, The oncologist.

[41]  Susan M. Chang,et al.  A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. , 2006, Neuro-oncology.

[42]  G. Kroemer,et al.  The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death , 2005, Journal of Cell Science.

[43]  Brent A Reynolds,et al.  Neural stem cells and neurospheres—re-evaluating the relationship , 2005, Nature Methods.

[44]  Philippe Dessen,et al.  Inhibition of Macroautophagy Triggers Apoptosis , 2005, Molecular and Cellular Biology.

[45]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[46]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[47]  M. Gilbert,et al.  Irinotecan: promising activity in the treatment of malignant glioma. , 2003, Oncology.

[48]  A. Matsumura,et al.  Competitive uptake of porphyrin and LDL via the LDL receptor in glioma cell lines: flow cytometric analysis. , 2001, Cancer letters.

[49]  M. Mccarty,et al.  Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation. , 2001, Medical hypotheses.

[50]  J. Willson,et al.  Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[52]  G. Rudenko,et al.  N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. , 1993, The Journal of biological chemistry.

[53]  R. Hruban,et al.  Multidrug resistance gene (MDR1) expression in human brain tumors. , 1991, Journal of neurosurgery.

[54]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.